Lilly Partners With Gateway Labs Resident Amplitude on taRNA Vaccine Platform
Eli Lilly has enlisted Gateway Labs resident Amplitude Therapeutics to help develop trans-amplifying RNA (taRNA) vaccines for infectious diseases, with an option to add up to two additional targets. The partnership will initially pursue undisclosed high-unmet-need programs, aiming for improved potency, lower doses and better manufacturability. Financial terms were not disclosed.